Recombinant human erythropoietin - contemporary aspects of application in obstetrics

In the present article the review of modem literature on questions of physiology, biochemistry and the main aspects of use of erythropoietin is presented. Since 1985DNA-recombinant human erythropoietin (rhEPO), which is applied for the replacement therapy in patients with insufficient production of EPO, became accessible. Since 1997 the Russian preparation rhEPO «Epocrin» is permitted for clinical application. RhEPO in combination with adequate organism saturation with iron is noticed to stimulate erythropoesis effectively inpatients with anemia including pregnant women, postpartum women and premature infants as well.